
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cancer Epidemiology Biomarkers & Prevention, Vol 1, Issue 6 467-474, Copyright © 1992 by American Association for Cancer Research
ARTICLES |
IM Margulies, M Hoyhtya, C Evans, ML Stracke, LA Liotta and WG Stetler-Stevenson
Laboratory of Pathology, National Cancer Institute, NIH, Bethesda, Maryland 20892.
Accumulating experimental evidence has linked the overproduction of extracellular matrix-degrading metalloproteinases with tumor cell invasion. In the present study one member of the metalloproteinase family, type IV collagenase (M(r) 72,000 gelatinase), is shown to be elevated in the urine of patients with transitional cell carcinoma of the bladder. The form of the enzyme in the urine was studied by three independent methods: enzyme-linked immunosorbent assay, Western immunoblotting; and gelatin zymography. Immunoblotting revealed that the enzyme was present as a series of fragments, each retaining the amino terminus of the mature proenzyme. A prominent M(r) 43,000 fragment was associated with the transitional cell carcinoma cases. Zymography demonstrated that multiple enzyme species with gelatinase activity were present in urine and that high-molecular-weight bands of substrate lysis corresponded to complexes between type IV collagenase and tissue inhibitor of metalloproteinases 2. The total amount of type IV collagenase antigen was significantly elevated in the urine of 37 transitional cell carcinoma patients (range, 0-1081 ng/ml; mean, 318.4 +/- 147.3) compared to 19 normal controls (P < or = 0.004) and 17 inflammatory disease controls (P < or = 0.011). Immunohistochemical staining of bladder tumor biopsies verified that the transitional cell carcinoma cells were producing the M(r) 72,000 enzyme. Thus, M(r) 72,000 type IV collagenase, which is present in the urine in many forms including fragments and complexes with inhibitors, may be a useful marker for bladder cancer diagnosis or prognosis.
This article has been cited by other articles:
![]() |
P. K. Grover, L. A. Thurgood, D. E. Fleming, W. van Bronswijk, T. Wang, and R. L. Ryall Intracrystalline urinary proteins facilitate degradation and dissolution of calcium oxalate crystals in cultured renal cells Am J Physiol Renal Physiol, February 1, 2008; 294(2): F355 - F361. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Segrelles, S. Ruiz, M. Santos, J. Martinez-Palacio, M. F. Lara, and J. M. Paramio Akt mediates an angiogenic switch in transformed keratinocytes Carcinogenesis, July 1, 2004; 25(7): 1137 - 1147. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Yan and M. A. Moses A Case of Tumor Betrayal : Biphasic Effects of TIMP-1 on Burkitt's Lymphoma Am. J. Pathol., April 1, 2001; 158(4): 1185 - 1190. [Full Text] [PDF] |
||||
![]() |
G. Davis, K. Pintar Allen, R Salazar, and S. Maxwell Matrix metalloproteinase-1 and -9 activation by plasmin regulates a novel endothelial cell-mediated mechanism of collagen gel contraction and capillary tube regression in three-dimensional collagen matrices J. Cell Sci., January 3, 2001; 114(5): 917 - 930. [Abstract] [PDF] |
||||
![]() |
C. F. M. Sier, G. Casetta, J. H. Verheijen, A. Tizzani, V. Agape, J. Kos, F. Blasi, and R. Hanemaaijer Enhanced Urinary Gelatinase Activities (Matrix Metalloproteinases 2 and 9) Are Associated with Early-Stage Bladder Carcinoma: A Comparison with Clinically Used Tumor Markers Clin. Cancer Res., June 1, 2000; 6(6): 2333 - 2340. [Abstract] [Full Text] |
||||
![]() |
H. Y. Lee, T. Clair, P. T. Mulvaney, E. C. Woodhouse, S. Aznavoorian, L. A. Liotta, and M. L. Stracke Stimulation of Tumor Cell Motility Linked to Phosphodiesterase Catalytic Site of Autotaxin J. Biol. Chem., October 4, 1996; 271(40): 24408 - 24412. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Yan, N. Borregaard, L. Kjeldsen, and M. A. Moses The High Molecular Weight Urinary Matrix Metalloproteinase (MMP) Activity Is a Complex of Gelatinase B/MMP-9 and Neutrophil Gelatinase-associated Lipocalin (NGAL). MODULATION OF MMP-9 ACTIVITY BY NGAL J. Biol. Chem., September 28, 2001; 276(40): 37258 - 37265. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |